You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-TAM Receptor (Tyro3-Axl-Mer)-MRX-2843
MRX-2843

Chemical Structure : MRX-2843

CAS No.: 1429882-07-4

MRX-2843 (UNC2371, MRX2843)

Catalog No.: PC-49059Not For Human Use, Lab Use Only.

MRX-2843 (UNC2371) is a potent, selective, orally available ATP-competitive type 1 inhibitor of both Mer and Flt3 with IC50 of 1.3 and 1.0 nM, respectively.

Packing Price Stock Quantity
5 mg $158 In stock
10 mg $248 In stock
25 mg $428 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

MRX-2843 (UNC2371) is a potent, selective, orally available ATP-competitive type 1 inhibitor of both Mer and Flt3 with IC50 of 1.3 and 1.0 nM, respectively.
MRX-2843 shows 15-fold selectivity for these kinases over the other members of the TAM-family, AXL and TYRO-3 (IC50=15 and 17 nM), and other relevant tyrosine kinases.
MRX-2843 (10-100 nM) inhibits MERTK activation and mediates functional antileukemia effects in MERTK-dependent AML models, inhibits MERTK phosphorylation, MRX-2843 (25-300 nM) inhibits downstream signaling through pathways (phosphorylation of ERK1/2, AKT, and STAT6) in Kasumi-1 cells.
MRX-2843 inhibits FLT3 activation and mediates functional antileukemic effects in FLT3-ITD AML models, inhibitsphosphorylation of FLT3 and downstream signaling through STAT5, ERK1/2, and AKT, inhibits clonal expansion in MOLM-14 cultures (IC50=29.5 nM).
MRX-2843 selectively inhibits colony formation in primary AML patient samples and prolongs survival in patient-derived xenograft models of AML.

Physicochemical Properties

M.Wt 488.680
Formula C29H40N6O
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

trans-4-[2-[(2-Cyclopropylethyl)amino]-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanol

References

1. Minson KA, et al. JCI Insight. 2016 Mar;1(3):e85630.

2. Yan D, et al. Clin Cancer Res. 2018 Dec 15;24(24):6523-6535.

3. Yan D, et al. J Clin Invest. 2022 Jun 16:e150517.

4. Zhang W, et al. J Med Chem. 2014;57(16):7031–7041.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: